Pacific Biosciences of California, Inc.

PACB Healthcare Medical Devices

Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.73 0.23 −11.73%
Market cap
$609.2M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
3/9
Altman Z
−6.04
Beneish M
−5.14
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
279.53 390.62 631.72 772.62 1,044.90 319.65 49.40 102.35 62.87 71.98
Receivables
35.45 27.52 36.62 18.79 24.24 16.84 15.27 8.60 13.43 11.42
Inventory
49.29 58.76 56.68 50.38 24.60 14.23 13.31 17.88 23.07 15.63
Total current assets
375.05 495.68 742.05 852.07 1,101.13 355.59 81.05 131.66 101.62 109.01
Property, Plant, Equpment (Net)
24.15 30.51 36.43 41.58 32.50 24.90 30.07 34.07 37.92 14.56
Goodwill and Intangible Assets (Total)
332.89 707.33 919.25 820.22 820.95 — — — — —
Long-term assets (Other)
10.31 10.84 15.70 13.45 5.76 3.54 4.04 4.54 4.55 14.31
Total non-current assets
409.03 764.77 1,003.97 915.01 905.84 58.39 66.94 38.62 42.47 28.87
Total Assets
784.08 1,260.45 1,746.01 1,767.09 2,006.97 413.98 147.99 170.28 144.08 137.88
Notes Payable
— — — — — — 15.87 — — —
Accounts Payable
20.77 16.59 15.06 12.03 11.00 3.58 8.37 6.74 9.09 8.36
Accrued Expenses
33.65 22.60 45.71 32.60 36.26 17.35 13.24 12.82 12.62 16.60
Current Revenue (Deferred)
15.94 13.86 16.34 30.50 10.98 8.72 7.61 6.54 6.32 7.13
Other current liabilities
2.03 3.22 8.33 179.33 5.76 4.52 0.23 0.79 0.61 1.68
Total current liabilities
72.83 66.30 95.03 263.34 71.71 38.50 49.15 26.88 28.64 33.77
Long Term Debt (Total)
645.38 647.49 892.24 896.68 896.07 38.00 42.00 14.66 13.64 16.11
Non-current Revenue (Deferred)
3.93 5.90 5.53 1.79 25.05 1.57 1.95 14.66 1.08 1.32
Non-current Liabilities (Other)
— 19.25 20.30 1.30 173.19 0.75 — 0.02 14.64 2.02
Total non-current liabilities
705.90 687.55 949.68 940.85 1,144.27 39.99 43.92 29.33 29.35 19.44
Total liabilities
778.73 753.85 1,044.71 1,204.18 1,215.98 78.49 93.07 56.21 57.98 53.22
Additional Paid In Capital
2,699.89 2,654.80 2,539.89 2,099.78 2,009.95 1,372.08 1,121.00 1,096.05 965.75 872.11
Common Stock (Net)
0.30 0.29 0.27 0.23 0.22 0.19 0.15 0.15 0.12 0.09
Retained Earnings
(2,695.30) (2,148.93) (1,839.07) (1,532.34) (1,218.09) (1,036.87) (1,066.24) (982.11) (879.73) (787.54)
Common Equity (Total)
5.35 506.59 701.30 562.90 790.99 335.49 54.92 114.06 86.10 84.67
Shareholders Equity (Total)
5.35 506.59 701.30 562.90 790.99 335.49 54.92 114.06 86.10 84.67
Shareholders Equity and Liabilities (Total)
784.08 1,260.45 1,746.01 1,767.09 2,006.97 413.98 147.99 170.28 144.08 137.88
Shares (Common)
301.96 294.42 267.74 226.51 220.98 192.29 153.12 150.24 116.28 92.68
Shareholders Equity (Tangible)
(327.54) (200.74) (217.94) (257.31) (29.97) 335.49 54.92 114.06 86.10 84.67
Net Debt
365.86 256.87 260.53 124.07 (148.83) (281.65) (7.40) (87.69) (49.24) (55.87)
Total Debt
645.38 647.49 892.24 896.68 896.07 38.00 42.00 14.66 13.64 16.11

Fold the line items

In millions of $ except per-share values · columns are period end dates